V ascular disease is the leading cause of mortality and morbidity in the United States. Coronary artery disease, cerebrovascular disorders, pulmonary venous thromboembolism, and systemic and pulmonary hypertension account for one third of the national annual mortality. Traditionally, the practice of cardiology has emphasized the diagnosis and treatment of the sequelae of these disorders. This approach has been exemplified by major advances in cardiovascular surgery, interventional catheter techniques, and heartlung transplantations, to name a few. Recently, major conceptual shifts have occurred in our approach to vascular disease. Increasingly, we recognize the importance of preventive cardiology and the need to understand the fundamental mechanisms mediating these disorders. Specifically, there is an explosion of new information on the complex and intricate processes that maintain homeostasis of the vessel wall and the pathobiological events that result in vascular diseases. We believe that the future in the management of vascular disease will depend on the development of novel diagnostic and therapeutic strategies based on our growing knowledge of vascular biology. This article is intended to review the latest developments in vascular biology and provide our perspectives on the future of the emerging discipline of vascular medicine.
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The concept of vascular biology and medicine has evolved dramatically from William Harvey's1 original description of the circulation in which the vasculature was conceived as a passive conduit transporting blood to and from vital organs. It is now recognized that the vasculature is a complex organ capable of sensing its environment, transducing signals to the cells within the vasculature or to the surrounding tissue, and synthesizing local mediators that promote functional or structural responses. A constant feature of these interactionsproinflammatory mediators as well as anti-inflammatory agents, and growth stimulators as well as inhibitors. Disturbances in this delicate balance may play a role in the development of vascular pathology.
For example, a common feature of many forms of vascular diseases is that endothelial function is impaired. Metabolic, mechanical, and immunologic injury to the endothelium may disturb the homeostatic balance within the vasculature by inducing endothelial dysfunction. Given its role as a regulator of vascular tone, structure, hemostasis, and the inflammatory response, any dysfunction of the endothelium may have profound effects on the state of the vasculature. In addition to the endothelium, other cells within the vasculature may also participate in the regulation of vascular function and structure. In particular, smooth muscle cells and infiltrating macrophages release a variety of mediators that modulate vessel tone, hemostatic balance, cell growth, extracellular matrix production, and inflammation. Further elucidation of these cellular interactions and the autocrine and paracrine effects of the mediators released by cells within the vessel wall should provide novel insights into the understanding and treatment of vascular disease.
Advances in vascular biology have depended on the contributions of investigators from multiple disciplines (e.g., cell biology, pathology, cardiology, hematology, molecular genetics, hypertension, lipid metabolism, etc.). Thus, the investigators in vascular research face the difficult challenges of synthesizing and analyzing a broad and diversified body of data and of applying the knowledge of vascular biology to the understanding of the pathogenesis of vascular disease and the development of novel therapeutic strategies for the future.
In order to review systematically this broad topic of vascular biology and medicine, this article is organized into four major sections. The first focuses on the biology of the vessel wall, with an initial review of the autocrine and paracrine functions of the blood vessels, with particular emphasis on the endothelium. These include the sensory functions of the endothelium as well as the mediators involved in the homeostatic control of vascular tone, hemostasis, and vascular structure. This section also examines cell-cell interactions at the endothelium-blood interface. In addition, it includes discussions regarding the mechanisms of incorporation of lipoproteins, the organization of the extracellular matrix within the vessel wall, and how abnormalities of these interactions may lead to pathological states in humans. In the second section, we will review the pathobiological mechanisms of vascular diseases. A better understanding of these pathological conditions has resulted from studies of animal models. Accordingly, specific models of vascular diseases ranging from balloon injury to transgenic animals will be examined, with emphasis on the relevance to human disease in the second section. Next, we focus on new perspectives and future directions in vascular medicine and therapy based on the advances in vascular biology. Treatment modalities range from endovascular reconstruction to antibody-targeted drug therapy to gene therapy as components of emerging strategies in the 1990s. Finally, we discuss the importance of applying the biology of blood vessels to clinical practice and the need for training physicians and scientists in this emerging frontier of vascular biology and medicine.
Biology of the Vessel Wall Autocrine-Paracrine Mechanisms of Vascular Responses
Let us first examine the mechanisms by which the blood vessel detects changes in the circulation and regulates its function and structure. A key element in the vessel wall responsible for these functions is the endothelium. The endothelium is strategically located to serve as a sensory tissue assessing hemodynamic conditions such as blood flow and pressure as well as ambient oxygen status.2'3 In addition, the endothelium participates in the modulation of flow and pressure by its response to circulating vasoactive and other humoral substances as well as its own production of biological mediators. [2] [3] [4] [5] [6] The capacity to sense conditions within the local environment of the blood vessel is mediated via specific receptor-activated cellular events. 7 Vasoactive substances such as bradykinin, inflammatory mediators such as platelet activating factor, and factors involved in hemostasis such as thrombin all evoke changes in phosphoinositol metabolism and increases in intracellular calcium within endothelial cells by this mechanism. In addition, these mediators also activate ion channels within the endothelium by receptor-coupled mechanisms. These second messenger systems in turn induce cellular events that enable endothelial cells to regulate tone, inflammation, and hemostasis. [8] [9] [10] [11] [12] [13] [14] [15] In this review, for the purpose of focus, we will limit the discussion to the capacity of the vessel to sense and respond to hemodynamic stimuli. It In response to the hemodynamic and humoral changes, the vessel wall (especially the endothelium) synthesizes and secretes biologically active substances that secondarily control its tone and structure.2 Thus, increased flow or shear stress is associated with increased production of endothelium-derived relaxing factor (EDRF) and prostaglandins as well as decreased endothelin mRNA levels and reduced secretion of the peptide. 4 In any vascular response, one observes a net balance between the effects of stimulators of cell migration/proliferation and inhibitors of these same phenomena. In addition, each cell type within the vessel wall appears to have the capacity to produce factors that influence cell migration and proliferation in an autocrine or paracrine fashion. VSMCs and the endothelium produce a variety of growth regulatory substances such as PDGF, bFGF, insulin-like growth factor 1 (IGF-1), TGF-f81, colony stimulating factor 1, interleukin-1 (IL-1), modified LDL, prostaglandins, and EDRF. In addition, bloodborne elements such as platelets and monocyte/macrophages also contain or synthesize thrombin, plateletderived endothelial cell growth factor (PD-ECGF), epidermal growth factor, TGF-a, TGF-f31, bFGF, PDGF, modified LDL, IL-i, heparin-binding epidermal growth factor (HB-EGF), and tissue necrosis factor (TNF). The induces a downregulation of the receptor for the PDGF-AA homodimer. Hence, the net growth response to TGF-p1 may depend on the concentration of the peptide and the relative abundance of receptors for the PDGF-AA homodimer. 73 Elucidation of the pathogenesis of these lesions not only depends on defining the interactions among growth factors and their receptors but also defining the relative proportion of different cell types within the lesion. Recent immunohistochemical studies suggest that inflammatory cells are present at early stages of the vascular lesions of hypertension as well as vascular injury.80,81 These findings imply that the actual differences in the pathogenesis of hypertensive vascular disease and that characterized by an obvious inflammatory response such as transplant arteriosclerosis may be more quantitative than qualitative.81 Each of these clinical disease subtypes may actually be part of the same spectrum of vascular disease involving similar pathophysiological mechanisms.
Advances in molecular biology have enabled investigators to progress beyond morphological description of lesion composition to a description of the mediators involved in the pathogenesis of the lesion. Analysis of growth regulatory peptide expression in the vascular lesions of hyperlipidemic models demonstrates the expressions of these genes in several cell types within the lesion including endothelial cells, smooth muscle cells, and macrophages. There is increased gene expression of the PDGF ,-type receptor, the oncogene c-fms (which encodes colony-stimulating factor 1), and TGF-f31. Approximately 20% of macrophages expressed the PDGF B chain, but lipid-laden macrophages and smooth muscle cells were negative for this peptide.82 Proliferating cell nuclear antigen immunoreactivity, a marker of cell proliferation, was detected in smooth muscle cells that also expressed the PDGF A chain within vascular lesions.83
These findings are consistent with the notion that these lesions evolve as a result of the interaction of several cell types and multiple growth regulatory substances. Further definition of the mediators and modulators of vascular cell growth in vascular disease is one of the major tasks in vascular biology and medicine in the 1990s.
The Blood Vessel as an Interface Between Circulating and Tissue Factors
Given the multidimensional capabilities of the vasculature and the strategic location of the vessel as the interface between blood and the tissues, the blood vessel plays an important role in first-line defense against factors that may induce tissue damage. The response to these injurious agents is often complex and may lead to pathology. As discussed above, the evolution of atherosclerotic vascular disease involves many processes such as the infiltration of leukocytes into the vessel wall, alterations in lipid metabolism, cell migration through the extracellular matrix, and eventually, thrombosis caused by platelet aggregation at the site of stenosis. Each of these components appears to involve the interaction of specific ligands and cell surface receptors categorized as adhesion molecules. The expression of these molecules may be an important aspect induction of autocrine PDGP--AA production by the-of the pathological process. In this section, we will examine the role of adhesive molecules governing cell migration and the effect of these cell-cell interactions on lipoprotein metabolism.
The endothelium as the interface between the blood stream and the vessel wall is ideally situated to function as a gatekeeper regulating the traffic of cell movement from the circulation to sites within tissues. It has become increasingly apparent that the endothelial lining is a complex and heterogeneous structure. The adherence of cells onto the endothelial surface and the transmigration through the vessel wall is dependent on specific interactions that involve cell surface receptors and matrix proteins.1884-86 The process of cell localization involves a complex interplay between the molecules that govern cell adherence and local cytokines and chemotactic factors that modulate binding site availability and direct cell migration.
The adhesive molecules involved in endothelial cell interactions are composed of three basic families: the immunoglobulin superfamily, which includes the antigen-specific receptors of T 
Pathobiology of Vascular Diseases
Research in vascular biology has improved our understanding of the pathophysiology of vascular diseases. It has been demonstrated that disturbances in vascular homeostasis can result in pathological conditions such as hypertension, thrombosis, atherosclerosis, and restenosis. Advances in these areas have depended on research using cell and molecular techniques, pathological studies, clinical investigations, and animal experimentation. The application of the knowledge of vascular biology to medicine is enhanced by the development of animal models of clinical diseases that allow investigators to examine specific hypotheses, elucidate the pathophysiology of disease processes, and test the potential efficacies of therapeutic modalities. Animal models of atherosclerosis have been studied for many years, and the pathobiology of this disease has been reviewed in the preceding section as well as in other publications.6,7 Although many forms of vascular diseases exist, this article will emphasize the use of molecular and cell biological technology in the studies of four major vascular disorders: myointimal hyperplasia, transplant arteriosclerosis, hypertension, and angiogenesis. In addition, the utility of the transgenic approach to the study of vascular disease will also be discussed. The following
Myointimal Hyperplasia
It has been postulated that the lesion of atherosclerosis develops in response to vascular injury. However, the precise nature of the vascular injury remains poorly defined. A large body of evidence has demonstrated that mechanical injury to the vessel wall induced by a balloon catheter stimulates the proliferation and migration of VSMCs into the subintimal space. This process of myointimal proliferation is characteristic of at least one component of the pathogenesis of atherosclerosis and therefore serves as a useful model of vascular disease.
Ironically, mechanical vascular injury is the principle underlying the current use of balloon angioplasty: Percutaneous balloon angioplasty mechanically initiates a pathological remodeling process within the vessel wall that produces luminal patency. However, the resultant myointimal hyperplasia induced in response to vascular injury produces clinically significant restenosis in over 30% of cases within 6-9 months. 102 The loss of endothelium and platelet adherence that accompanies balloon injury were considered to be important initial events triggering the proliferative response. It Given the complexity of this pathological process combined with the difficulty of avoiding adverse effects of treatment, it seems unlikely that a "magic bullet" will be discovered that selectively blocks a single mediator to prevent restenosis. Further research will be necessary to identify a circumscribed set of final common pathways that are essential for the pathogenesis of lesion formation. A multipronged therapeutic strategy directed at specific cellular pathways necessary for cell adhesion, proliferation, migration, and matrix production may be necessary to prevent restenosis. Effective preventive strategies developed for restenosis after angioplasty may also be useful in improving the efficacy of other revascularization techniques such as stents, atherectomy, and vein grafts.
Cardiac Transplant Arteriosclerosis
Although advancements in immunosuppression therapy have improved the early survival of recipients of heart transplants, the long-term success of the graft is limited by the development of transplant arteriosclerosis. 125 The morphological appearance of transplant arteriosclerosis is distinct from classic atherosclerosis lesions in that it is mostly diffuse and concentric without significant lipid accumulations.126 This form of vascular disease, characterized by myointimal hyperplasia, is particularly interesting because it follows an accelerated course and occurs in vessels that were previously "normal." This "complication" of transplant technology provides a unique opportunity to study the roles of immune injury, endothelial cell dysfunction, and vascular proliferation in the pathogenesis of vascular lesions in humans.
The factors involved in the pathogenesis of these lesions remain to be defined. Possible contributory factors include the immunosuppressive agents themselves, viral infections (e.g., cytomegalovirus'27), as well as the hyperlipidemia and hypertension that are prevalent among these patients. It remodeling in hypertension involves changes in the association with this antiproliferative effect. In addition, the constitutive expressions of both IL-1 and cyclooxygenase mRNAs increase with the number of passages until the cells achieve a senescent state. Indeed, blockade of IL-i expression with antisense IL-i oligonucleotides promotes the extension of the cell life span. 143 These provocative observations suggest a role for autocrine or "intracrine" growth factors in the cellular transitions between states of proliferation, quiescence/ differentiation, and senescence. It seems likely that the lack of a signal sequence is an important regulatory mechanism that limits the local effects of these potent growth factors, thereby maintaining tissue homeostasis. Understanding the mechanisms regulating the transitions between states of differentiation from proliferation to senescence is a fundamentally important biological problem that has important pathophysiological implications.
Transgenic Approach to Studies of Vascular Disease
The utilization of transgenic technology is an important approach to develop genetic models of vascular disease and examine the molecular mechanisms of pathological conditions in the future. It is now well established that foreign DNA molecules can be stably introduced into the germ line of experimental animals. This can be accomplished by direct microinjection of the DNA into the pronucleus of a fertilized egg, followed by reimplantation of the microinjected embryos into a suitable foster host. A fraction of the pups derived from the microinjected embryos will have incorporated the foreign DNA into their genome, and in most instances the newly acquired sequences will be passed on to subsequent generations in a mendelian fashion. Alternatively, the foreign DNA can be introduced via methodologies that rely on either the retroviral infection of embryos or by transfection of pluripotent embryonic stem cells. Each of these approaches can generate experimental "transgenic" animals that differ from the wild type by the addition or deletion of a single, defined gene. It is anticipated that the use of transgenic technology will facilitate the assessment of the complex interactions of genes and their products involved in cardiovascular homeostasis. Through the use of transgenics, individual components of these regulatory cascades can be altered so that cause and effect can be established. 144 Another application of this technology involves the generation of cell lines from rare or intractable cell types. Typically, fusion genes are constructed such that expression of the oncogene is regulated by the promoter of the gene of interest and targeted to the cell type of interest. Expression of the oncogene is therefore tissue and gene specific, which in turn results in the targeted tumor formation from which cell lines can be derived.144 '145 For example, fusion of the atrial natriuretic factor (ANF) gene promoter to the oncogene SV40 T antigen resulted in the generation of mice with a fourfold increase in basal plasma ANF levels.146 The significant reduction in baseline blood pressure observed in the transgenic animals is an intriguing observation that implies that ANF may play a more important role in the long-term regulation of blood pressure than previously believed.147 Consistent with the importance of ANF in fluid homeostasis, the administration of a volume load by intravenous infusion induced a potentiated natriuresis in the transgenic animals without a change in glomerular filtration rate.148 Moreover, it was possible to isolate atrial cells from animals that proliferate in vitro and yet retain certain phenotypic properties such as ANF granules, myosin filaments, and T-tubules. 145 In addition to ANF, a number of transgenic models of cardiovascular diseases have been reported. These include models of hypertension, altered lipid metabolism, thrombosis, and vascular and cardiac hypertrophy.144,146-152 It is not difficult to predict that this technology will be very fruitful in the advancement of vascular biology and drug development in the i990s.
Vascular Diagnosis and Therapy in the 1990s
Many of the exciting advancements in the area of vascular biology and medicine have been discussed in this review. It is evident that this field encompasses multiple disciplines and broad research activities. A major task for the 1990s is to integrate these activities under the common goal of vascular medicine. It is hoped that as we gain greater understanding of the mechanisms regulating vascular tone, hemostasis, lipoprotein metabolism, inflammation, and structure with the vessel wall, we will be able to apply our knowledge to the diagnosis and treatment of vascular disease.
Advancements in technology have expanded the capacity to diagnose vascular disease. Innovations such as angioscopy153 have helped to clarify the pathophysiology of acute ischemic syndromes by providing an intraluminal view of the blood vessel. It is anticipated that this technique will be a useful adjunct to other endovascular procedures such as laser angioplasty and atherectomy. Similarly, intravascular ultrasoundl54 shows promise as a tool that will complement angioscopy and angiography by providing a view of the blood vessel wall beyond the lumen. Intravascular ultrasound provides the capability of early detection of nonobstructive atherosclerosis and may be useful for the evaluation of treatment modalities to prevent or regress atherosclerosis and to detect and longitudinally follow early arteriosclerosis (e.g., in heart transplants) and other vascular lesions. Future investigations using this device will characterize the morphology of the vessel wall and will undoubtedly provide novel insights into the process of vascular remodeling in humans.
In addition to these diagnostic tools, technological innovations will also expand the therapeutic armamentarium in the fight against vascular disease. It is conceivable that the progress in the treatment ofvascular disease such as that produced by balloon angioplasty may be eclipsed by the emergence of new generations of endovascular procedures.155 These include the use of laser technology and atherectomy catheters to remove atheromatous plaques as well as mechanical stents that physically remodel the diseased vessel wall. Given the ubiquitous problem of restenosis, it is anticipated that mechanical endovascular reconstruction will be coupled to adjunctive therapies that reduce the risk of restenosis.
Agents are being developed that inhibit thrombosis and/or myointimal proliferation. These Disease. The purpose of these awards is to foster educational and clinical programs, which will integrate physicians from diverse disciplines who have skills in various facets of vascular disease (hypertension, coronary artery disease, thrombosis, and lipid and glucose metabolism). This multidisciplinary approach will provide integrated care for the patient with vascular disease and improve upon our current fragmented approach. The integration of these disciplines of medicine will not only provide superior patient care but will also provide an enriched environment for training in vascular medicine. The program guidelines promulgated by the NHLBI define vascular medicine as that clinical discipline which has as its objectives "the clinical characterization of all vascular diseases (arterial, venous, lymphatic, cerebral, coronary, pulmonary, aortic, renal, and peripheral), the pathogeneses of these diseases (including atherosclerosis, lipid metabolic disorders, systemic and pulmonary hypertension, lymphedema, thrombosis, vasculitis, and vasospastic disorders), as well as the diagnostic, therapeutic, and preventive approaches to these diseases."
In 1991, vascular medicine programs at Stanford and Harvard universities were funded through this mechanism, and plans are to provide NHLBI sponsorship for additional programs in the near future.
These integrative research and training efforts should result in the development of a new generation of clinicians and scientists with expertise in the principles and applications of vascular medicine. Physicians trained in vascular biology and medicine may pursue academic careers in vascular research and by so doing will facilitate the clinical application of new concepts in vascular pathophysiology. Others will focus on improving education in vascular medicine at the medical school and postgraduate levels. Practitioners trained in these programs will provide expert consultation to their medical colleagues and will complement the work of radiologists, surgeons, and others interested in vascular diseases. The advantages that will accrue to our patients from this enlightened and integrated care and from the advances in vascular therapeutic research provide compelling rationale for moving ahead with these programs.
Recognition of the clinical and scientific potential of vascular medicine and biology has led to new programs at many medical centers, including our own. This trend, which has been fostered by the NIH, AHA, and ACC, promises to provide new discoveries, to generate new concepts, and to find novel solutions for vascular diseases in this decade. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme-inhibitor complexes. 
